|Asterias Biotherapeutics Announces Closing of $10.4 Million Registered Direct Offering|
October 19, 2017
|FREMONT, Calif., Oct. 19, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company focused on the field of regenerative medicine, today announced that it closed its previously announced registered direct offering of an aggregate of four million shares of its Series A common stock at an offering price of $2.60 per share, for aggregate gross proceeds of approximately $10.4 million.
Asterias intends to use the net proceeds from this offering for clin... |
|BioTime, Inc. Announces Closing of Public Offering and Underwriters’ Full Exercise of Over-Allotment Option|
October 17, 2017
|ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 17, 2017--
BioTime, Inc. (“BioTime”) (NYSE American and TASE: BTX), a late stage
clinical biotechnology company focused on developing and commercializing
products addressing degenerative diseases, today announced the closing
of its previously announced public offering of 9,615,385 shares of
common stock, including 1,442,308 shares sold pursuant to the
underwriters’ exercise in full of their option to purchase additi... |
|Asterias Biotherapeutics Announces $10.4 Million Registered Direct Offering|
October 16, 2017
|FREMONT, Calif., Oct. 16, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company focused on the field of regenerative medicine, today announced that it entered into a securities purchase agreement with certain institutional investors in connection with a registered direct offering, of an aggregate of four million shares of its Series A common stock at an offering price of $2.60 per share, for aggregate gross proceeds of approximately $10.4 million.... |
View Committee Composition
Find the latest financial information
DISCLAIMER: You are about to review presentations, reports, filings and/or other materials regarding BioTime, Inc. (NYSE: MKT and TASE: BTX) that contain time-sensitive information. The information contained therein is only current as of the date thereof. BioTime expressly disclaims any obligation to review, update or correct these materials after the date thereof. BioTime may update, amend, supplement or otherwise alter the information contained in any such materials by subsequent presentations, reports, filings, or other means without notice.
Certain statements made on this website or in materials accessed in or through this section of our website are "forward-looking statements," which are subject to risks and uncertainties, and BioTime's actual results may differ (possibly materially) from those indicated in such statements.
|Data provided by Nasdaq. Minimum 15 minutes delayed.|